EUCTR2008-003418-88-LV进行中（未招募）不适用
A Multicenter, Double-blind, Randomized Study Evaluating De Novo Weekly and OnceEvery 2 Week Darbepoetin alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed informed consent form/assent form (if applicable)
- •Diagnosis of CKD defined as stage 3 - 5 with an estimated GFR
- •< 60 mL/min/1.73m2 (Schwartz Equation)
- •Ages 1 year through 18 years
- •Two consecutive screening Hb values (taken at least 7 days apart during the
- •screening period) must be < 10.0 g/dL
- •Transferrin saturation (Tsat) = 20%
- •Clinically stable and suitable for participation in this study, in the judgment of
- •the investigator
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Anticipating or scheduled for a living related-donor kidney transplant
- •Prior history (within 12 weeks before randomization) of cardiovascular events
- •- acute myocardial ischemia
- •- hospitalization for congestive heart failure
- •- myocardial infarction
- •- stroke or transient ischemic attack
- •Hematologic disease (eg, sickle cell disease, myelodysplastic syndromes,
- •hematologic malignancy); myeloma; hemolytic anemia; thalassemia
- •Upper or lower GI bleeding within the 6 months prior to randomization
- •Uncontrolled hypertension defined as stage 2 hypertension or greater. This is
- •defined as a systolic or diastolic blood pressure value greater than the 99th
- •percentile + 5 mmHg for a subject’s age. See Appendix G. (Blood Pressure
- •Stages defined in the The Fourth Report on the Diagnosis, Evaluation, and
- •Treatment of High Blood Pressure in Children and Adolescents” Pediatrics 2004)
- •Use of any erythropoietic-stimulating agent (ESA) within 12 weeks before
- •randomization. Any use of an ESA prior to 12 weeks before randomization,
- •with the exception of per label administration of: Aranesp®, EPOGEN®,
- •Procrit®, Mircera® , NeoRecormon®, Dynepo®, Eprex®; Binocrit®,
- •Abseamed®, Epoetin alfa Hexal®, Retacrit®, or Silapo®.
- •History of seizure
- •Major surgery within 12 weeks prior to randomization (excluding vascular access surgery)
- •Clinical evidence of current malignancy and/or receiving systemic
- •chemotherapy/radiotherapy with the exception of localized basal cell or
- •squamous cell carcinoma of the skin and cervical intraepithelial neoplasia
- •RBC transfusions within 12 weeks prior to randomization
- •Androgen therapy within 8 weeks prior to randomization
- •Currently receiving antibiotic therapy for systemic infection
- •Prior history (within 6 months prior to randomization) of thromboembolism (eg,
- •deep vein thrombosis or pulmonary embolism)
- •Peritoneal dialysis subjects with an episode of peritonitis within 30 days prior to randomization
- •Pregnant or breast-feeding, or planning to become pregnant within four weeks after the end of treatment. Females who have reached menarche must have a
- •negative serum pregnancy test (or definitive evidence to demonstrate lack of
- •pregnancy) within 21 days prior to randomization, unless there is a documented
- •history of amenorrhea.
- •Not willing to use effective contraception during treatment and for 1 month after the end of treatment
- •Other investigational procedures are excluded
- •Treatment with an investigational product or device within 30 days before
- •randomization or scheduled to receive an investigational product other than
- •those specified by this protocol during the course of this study
- •Has known sensitivity to any of the products to be administered during dosing
- •Subject or parent/legal guardian has any kind of disorder that compromises the ability of the subject or parent/legal guardian to give written informed consent
- •and/or to comply with study procedures
- •Subject is currently taking immunosuppressive agents, including
- •corticosteroids.
研究者
相似试验
进行中（未招募）
1 期
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney DiseaseTreatment of anemia with darbepoetin alfa in pediatric subjects with chronic kidney disease (CKD) receiving and not receiving dialysisMedDRA version: 14.1 Level: LLT Classification code 10064848 Term: Chronic kidney disease System Organ Class: 100000004857MedDRA version: 14.1 Level: LLT Classification code 10002272 Term: Anemia System Organ Class: 100000004851EUCTR2008-003418-88-GBAmgen Inc116
进行中（未招募）
不适用
A Multicenter, Double-blind, Randomized Study Evaluating De Novo Weekly and OnceEvery 2 Week Darbepoetin alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving DialysisEUCTR2008-003418-88-SKAmgen Inc180
进行中（未招募）
不适用
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney DiseaseEUCTR2008-003418-88-LTAmgen Inc180
进行中（未招募）
不适用
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney DiseaseTreatment of anemia with darbepoetin alfa in pediatric subjects with chronic kidney disease (CKD) receiving and not receiving dialysisMedDRA version: 17.0Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 17.0Level: LLTClassification code 10002272Term: AnemiaSystem Organ Class: 100000004851EUCTR2008-003418-88-Outside-EU/EEAAmgen Inc180
进行中（未招募）
1 期
A Multicenter, Double-blind, Randomized Study Evaluating De Novo Weekly and OnceEvery 2 Week Darbepoetin alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving DialysisTreatment of anemia with darbepoetin alfa in pediatric subjects with chronic kidneydisease (CKD) receiving and not receiving dialysisMedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseMedDRA version: 9.1Level: LLTClassification code 10002272Term: AnemiaEUCTR2008-003418-88-BEAmgen Inc180